Real-world Evidence Real-world tumor response rate can serve as a clinical endpoint, Friends pilot study showsFDA says raw images enrich the data when used with clinician assessments October 06, 2023Vol.49 No.37By Matthew Bin Han Ong
ASCO’s Julie Gralow: “There was clearly a shortage of drug, but there was a bigger problem of maldistribution” September 29, 2023Vol.49 No.36By Jacquelyn Cobb
Carolyn Bertozzi focused on bioorthogonal chemistry in 1996 and won the Nobel Prize in 2022This is how her discovery got to cancer clinical trials July 28, 2023Vol.49 No.30By Jacquelyn Cobb
Conversation with The Cancer Letter Nobel Prize-winning technology may enable delivery of up to 12x the standard doxorubicin dose July 28, 2023Vol.49 No.30By Jacquelyn Cobb
FreeTrials & Tribulations Engineering-level molecular diagnosis: A necessity for cancer treatment—and for a successful Moonshot July 21, 2023Vol.49 No.29By Michael P. Castro
Using ctDNA as an endpoint in your cancer clinical trial? FDA wants to hear from you July 14, 2023Vol.49 No.28By Matthew Bin Han Ong
Can ctDNA be used as an endpoint for cancer drug development?Friends collaboration to present initial results July 11 July 07, 2023Vol.49 No.27By Matthew Bin Han Ong
In the era of immunotherapy and targeted therapies, ODAC focuses on dose optimization in children June 23, 2023Vol.49 No.25By Jacquelyn Cobb
Trials & Tribulations We need better communication to enable patients to thrive in cancer survivorship June 23, 2023Vol.49 No.25By Lauren Ghazal and Fumiko L. Chino
An oncologist’s nightmare: “As of today, we no longer have any supply of carboplatin.” June 16, 2023Vol.49 No.24By Paul Goldberg
